During the corresponding time, Clearside Biomedical Inc saw a revenue deteriorated by -80.64 % year on year, sequentially revenue fell by -59.15 %. While revenue at the Clearside Biomedical Inc 's corporate clients
Clearside Biomedical Inc's Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs for products, primarily within the healthcare sector. Its market segments include federal health programs, private third-party payors, Medicaid, and other state healthcare programs. The entities involved encompass healthcare providers, health plans, healthcare clearinghouses, and business associates of covered entities, all of which handle protected health information in compliance with HIPAA regulations.
In the realm of ophthalmology, the continual quest for innovative treatments to address macular diseases has garnered significant attention, and Clearside Biomedical Inc. stands at the forefront of this endeavour. At the prestigious Association for Research in Vision and Ophthalmology (ARVO) 2025 meeting, emerging evidence was showcased through six compelling presentations that elucidated the efficacy of Clearside’s suprachoroidal platform. This platform is increasingly recognised as a transformative approach to expanding the standard of care for multiple macular diseases, including but not limited to age-related macular degeneration and diabetic macular edema.The suprachoroidal space, located between the ...
The article discusses the noteworthy contributions of Clearside Biomedical in the field of retinal drug development, as presented by Dr. Victor Chong at the Edridge Green Lecture. The subsequent publication of these insights in the peer-reviewed journal Eye underscores the significance of innovation and regulatory understanding in advancing retinal therapies, specifically via the novel suprachoroidal space (SCS) delivery method. This article aims to highlight the implications of these findings for future research and clinical application in ophthalmology.The field of retinal therapy has witnessed substantial evolution, addressing the complexities associated with delivering effective treatments to the back...
Clearside Biomedical and its partner Arctic Vision have announced promising results from their Phase 3 clinical trial of ARCATUS, a novel therapy designed for suprachoroidal use in treating uveitic macular edema. This breakthrough highlights a pivotal advancement in the therapeutic landscape of ophthalmology. Positive Topline Results Arctic Vision reported that the Phase 3 clinical trial of ARCATUS has met both its primary and secondary endpoints, heralding a new era for patients suffering from uveitic macular edema in China. The trial outcomes demonstrated significant efficacy of ARCATUS, supporting its potential as a groundbreaking treatment option. Achieving the Primary Endpoints The trial’s primary en...
Clearside Biomedical Inc’s Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs for products, primarily within the healthcare sector. Its market segments include federal health programs, private third-party payors, Medicaid, and other state healthcare programs. The entities involved encompass healthcare providers, health plans, healthcare clearinghouses, and business associates of covered entities, all of which handle protected health information in compliance with HIPAA regulations.
Sources:
Clearside Biomedical Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Clearside Biomedical Inc’s corporate clients.
For your research, we’ve provided 9 tables on Clearside Biomedical Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
